JAMA lambastes Vioxx articles

The Journal of the American Medical Association called into question published clinical data and authorship surrounding Merck's Vioxx (rofecoxib) in a scathing editorial. 

The hubbub stems from two articles printed in the April 16 issue, which offer a microscopic look at documents obtained during Vioxx lawsuits and litigation.

JAMA asserts that “clinical trial articles and review articles related to rofecoxib frequently were written by unacknowledged authors who were employees of for-profit information industries…” Merck refuted the charges in a statement claiming that the JAMA reports related to Vioxx “are false, misleading or lack context.”
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.

Email Newsletters